South Korea considering changes to BE data requirements for generic fixed combinations
This article was originally published in SRA
Executive Summary
The Korea Food and Drug Administration may soon require bioequivalence data to be submitted with abbreviated new drug applications for fixed combination drug products. Taking the first step in that direction, the agency said it was organising a group consisting of industry, pharmacists and physicians to develop a guideline on the issue in January.